Clinical trial
A Phase 2, Single-masked, Multicentre Study to Evaluate the Safety and Efficacy of 2 Dose Levels of THR-317 for the Treatment of Diabetic Macular Oedema (DME)
NCT03071068 is registered in ClinicalTrials.gov with ThromboGenics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Single-masked, Multicentre Study to Evaluate the Safety and Efficacy of 2 Dose Levels of THR-317 for the Treatment of Diabetic Macular Oedema (DME)
- Lead sponsor
- ThromboGenics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 22, 2016
- Completion date
- April 30, 2018
- Enrollment
- 49 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.